In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 151 to 200 of 434

TitleTypeExpected publication date
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology testsDiagnostics guidanceTBC
Familial Breast Cancer: initial assessment and genetic testing (update)NICE guideline
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]Technology appraisal guidanceTBC
Fertility problems: assessment and treatment - update 1 and 2NICE guideline
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Technology appraisal guidanceTBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Technology appraisal guidanceTBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Technology appraisal guidance
Flow tDCSMedtech innovation briefingsTBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]Technology appraisal guidanceTBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]Technology appraisal guidanceTBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]Technology appraisal guidanceTBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic painMedical technologies guidanceTBC
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576Technology appraisal guidanceTBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]Technology appraisal guidanceTBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Technology appraisal guidanceTBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]Technology appraisal guidanceTBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]Technology appraisal guidanceTBC
Heart valve disease presenting in adults: investigation and management (transcatheter aortic valve implantation (TAVI) to treat aortic stenosis)NICE guidelineTBC
Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)NICE guidelineTBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]Technology appraisal guidance
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Technology appraisal guidanceTBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]Technology appraisal guidanceTBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596Technology appraisal guidanceTBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]Technology appraisal guidanceTBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579Technology appraisal guidanceTBC
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)Technology appraisal guidance
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]Technology appraisal guidanceTBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]Technology appraisal guidance
Implanting a baroreceptor stimulation device for resistant hypertensionInterventional procedures guidanceTBC
In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory deathInterventional procedures guidanceTBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Technology appraisal guidanceTBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]Technology appraisal guidanceTBC
Indoor air quality at homeQuality standardTBC
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders ID6430Technology appraisal guidanceTBC
Infection prevention and control updateQuality standardTBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]Technology appraisal guidanceTBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]Technology appraisal guidance
Insulin efsitora alfa for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]Technology appraisal guidanceTBC
Insulin efsitora alfa for treating type 2 diabetes ID6499Technology appraisal guidanceTBC
Insulin icodec for treating type 2 diabetes [ID6175]Technology appraisal guidanceTBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]Technology appraisal guidanceTBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Technology appraisal guidanceTBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]Technology appraisal guidanceTBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]Technology appraisal guidance
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]Technology appraisal guidanceTBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Kidney CancerNICE guideline

Results per page

  1. 10
  2. 25
  3. 50
  4. All